BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30089603)

  • 1. Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers.
    Tessema M; Rossi MR; Picchi MA; Yingling CM; Lin Y; Ramalingam SS; Belinsky SA
    Lung Cancer; 2018 Sep; 123():99-106. PubMed ID: 30089603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.
    Li C; Fang R; Sun Y; Han X; Li F; Gao B; Iafrate AJ; Liu XY; Pao W; Chen H; Ji H
    PLoS One; 2011; 6(11):e28204. PubMed ID: 22140546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
    Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
    J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas.
    Nguyen QN; Vuong LD; Truong VL; Ta TV; Nguyen NT; Nguyen HP; Chu HH
    Pathol Res Pract; 2019 May; 215(5):885-892. PubMed ID: 30723053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
    Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
    BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers.
    Divine KK; Pulling LC; Marron-Terada PG; Liechty KC; Kang T; Schwartz AG; Bocklage TJ; Coons TA; Gilliland FD; Belinsky SA
    Int J Cancer; 2005 Apr; 114(3):400-5. PubMed ID: 15578700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
    Aisner DL; Sholl LM; Berry LD; Rossi MR; Chen H; Fujimoto J; Moreira AL; Ramalingam SS; Villaruz LC; Otterson GA; Haura E; Politi K; Glisson B; Cetnar J; Garon EB; Schiller J; Waqar SN; Sequist LV; Brahmer J; Shyr Y; Kugler K; Wistuba II; Johnson BE; Minna JD; Kris MG; Bunn PA; Kwiatkowski DJ;
    Clin Cancer Res; 2018 Mar; 24(5):1038-1047. PubMed ID: 29217530
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.
    Grosse C; Soltermann A; Rechsteiner M; Grosse A
    PLoS One; 2019; 14(8):e0220691. PubMed ID: 31386689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
    Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
    Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers.
    Toyooka S; Tokumo M; Shigematsu H; Matsuo K; Asano H; Tomii K; Ichihara S; Suzuki M; Aoe M; Date H; Gazdar AF; Shimizu N
    Cancer Res; 2006 Feb; 66(3):1371-5. PubMed ID: 16452191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
    Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression.
    Pulling LC; Divine KK; Klinge DM; Gilliland FD; Kang T; Schwartz AG; Bocklage TJ; Belinsky SA
    Cancer Res; 2003 Aug; 63(16):4842-8. PubMed ID: 12941804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hot spot mutations in Finnish non-small cell lung cancers.
    Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S
    Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
    Hosgood HD; Pao W; Rothman N; Hu W; Pan YH; Kuchinsky K; Jones KD; Xu J; Vermeulen R; Simko J; Lan Q
    Respir Med; 2013 Nov; 107(11):1755-62. PubMed ID: 24055406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
    Dogan S; Shen R; Ang DC; Johnson ML; D'Angelo SP; Paik PK; Brzostowski EB; Riely GJ; Kris MG; Zakowski MF; Ladanyi M
    Clin Cancer Res; 2012 Nov; 18(22):6169-77. PubMed ID: 23014527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma.
    Lee Y; Jeon JH; Goh SH; Roh H; Yun JY; Kwon NJ; Choi JH; Yang HC; Kim MS; Lee JM; Lee GK; Han JY
    Lung Cancer; 2019 Oct; 136():15-22. PubMed ID: 31421257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.
    Bjaanæs MM; Fleischer T; Halvorsen AR; Daunay A; Busato F; Solberg S; Jørgensen L; Kure E; Edvardsen H; Børresen-Dale AL; Brustugun OT; Tost J; Kristensen V; Helland Å
    Mol Oncol; 2016 Feb; 10(2):330-43. PubMed ID: 26601720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR.
    Ha SY; Choi SJ; Cho JH; Choi HJ; Lee J; Jung K; Irwin D; Liu X; Lira ME; Mao M; Kim HK; Choi YS; Shim YM; Park WY; Choi YL; Kim J
    Oncotarget; 2015 Mar; 6(7):5465-74. PubMed ID: 25760072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.